REFERENCES
1. Testa U, Pelosi E, Castelli G. Endothelial progenitors in the tumor microenvironment. Adv Exp Med Biol 2020;1263:85-115.
2. Ribatti D, Scavelli C, Roccaro AM, Crivellato E, Nico B, Vacca A. Hematopoietic cancer and angiogenesis. Stem Cells Dev 2004;13:484-95.
4. Najafabadi M, Shamsasenjan K, Akbarzadehalaleh P. Angiogenesis status in patients with acute myeloid leukemia: from diagnosis to post-hematopoietic stem cell transplantation. Int J Organ Transplant Med 2017;8:57-67.
5. Bertolini F, Mancuso P, Gobbi A, Pruneri G. The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp Hematol 2000;28:993-1000.
6. Moehler TM, Neben K, Ho AD, Goldschmidt H. Angiogenesis in hematologic malignancies. Ann Hematol 2001;80:695-705.
7. Rajkumar SV, Mesa RA, Tefferi A. A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies. J Hematother Stem Cell Res 2002;11:33-47.
8. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta-Reviews on Cancer 2012;1825:29-36.
9. Moss LA, Jensen-Taubman S, Stetler-Stevenson WG. Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am J Pathol 2012;181:1895-9.
10. Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci 2020:21.
11. Murphy G, Nagase H. Localizing matrix metalloproteinase activities in the pericellular environment. Febs J 2010;278:2-15.
12. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011;41:271-90.
13. Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L. Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm 2013;2013:928315.
14. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67.
15. Medina MA, Martínez-Poveda B, Amores-Sánchez MI, Quesada AR. Hyperforin: more than an antidepressant bioactive compound? Life Sci 2006;79:105-11.
16. McGrowder DA, Miller FG, Nwokocha CR, et al. Medicinal herbs used in traditional management of breast cancer: mechanisms of action. Medicines (Basel) 2020;7:47.
17. Varghese R, Dalvi YB. Natural products as anticancer agents. Curr Drug Targets 2020; doi: 10.2174/1389450121999201230204526.
18. Park SH, Kim M, Lee S, Jung W, Kim B. Therapeutic potential of natural products in treatment of cervical cancer: a review. Nutrients 2021;13:154.
19. Quiney C, Billard C, Salanoubat C, Fourneron JD, Kolb JP. Hyperforin, a new lead compound against the progression of cancer and leukemia? Leukemia 2006;20:1519-25.
20. Borrelli F, Izzo AA. Herb-drug interactions with St John’s wort (Hypericum perforatum): an update on clinical observations. Aaps J 2009;11:710-27.
21. Feisst C, Pergola C, Rakonjac M, et al. Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo. Cell Mol Life Sci 2009;66:2759-71.
22. Menegazzi M, Masiello P, Novelli M. Anti-tumor activity of hypericum perforatum L. and hyperforin through modulation of inflammatory signaling, ROS generation and proton dynamics. Antioxidants (Basel) 2020;10:18.
23. Hostanska K, Reichling J, Bommer S, Weber M, Saller R. Hyperforin a constituent of St John’s wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines. Eur J Pharm Biopharm 2003;56:121-32.
24. Quiney C, Billard C, Faussat AM, et al. Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia. Leukemia 2006;20:491-7.
25. Liu JY, Liu Z, Wang DM, et al. Induction of apoptosis in K562 cells by dicyclohexylammonium salt of hyperforin through a mitochondrial-related pathway. Chem Biol Interact 2011;190:91-101.
26. Merhi F, Tang R, Piedfer M, et al. Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells. PLoS One 2011;6:e25963.
27. Liu YC, Lin KH, Hsieh JH, et al. Hyperforin Induces apoptosis through extrinsic/intrinsic pathways and inhibits NF-ĸB-modulated survival and invasion potential in bladder cancer. In Vivo 2019;33:1865-77.
28. Billard C, Merhi F, Bauvois B. Mechanistic insights into the antileukemic activity of hyperforin. Curr Cancer Drug Targets 2013;13:1-10.
29. Lorusso G, Vannini N, Sogno I, et al. Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent. Eur J Cancer 2009;45:1474-84.
30. Rothley M, Schmid A, Thiele W, et al. Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo. Int J Cancer 2009;125:34-42.
31. Dell’Aica I, Caniato R, Biggin S, Garbisa S. Matrix proteases, green tea, and St. John’s wort: biomedical research catches up with folk medicine. Clin Chim Acta 2007;381:69-77.
32. Quiney C, Billard C, Mirshahi P, Fourneron JD, Kolb JP. Hyperforin inhibits MMP-9 secretion by B-CLL cells and microtubule formation by endothelial cells. Leukemia 2006;20:583-9.
33. Allegra A, Tonacci A, Spagnolo EV, Musolino C, Gangemi S. Antiproliferative effects of St. John’s Wort, its derivatives, and other hypericum species in hematologic malignancies. Int J Mol Sci 2020:22.
34. Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia 2012;26:2176-85.
35. Rodriguez-Ariza A, Lopez-Pedrera C, Aranda E, Barbarroja N. VEGF targeted therapy in acute myeloid leukemia. Crit Rev Oncol Hematol 2011;80:241-56.
36. Nair R, Salinas-Illarena A, Baldauf HM. New strategies to treat AML: novel insights into AML survival pathways and combination therapies. Leukemia 2021;35:299-311.
37. Cucchi DGJ, Polak TB, Ossenkoppele GJ, et al. Two decades of targeted therapies in acute myeloid leukemia. Leukemia 2021;35:651-60.
38. Estey E. New treatments for acute myeloid leukemia: how much has changed? Leukemia 2021;35:45-6.
39. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000;95:309-13.
40. Padró T, Bieker R, Ruiz S, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002;16:1302-10.
41. Fiedler W, Graeven U, Ergün S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997;89:1870-5.
42. Ghannadan M, Wimazal F, Simonitsch I, et al. Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category. Am J Clin Pathol 2003;119:663-71.
43. Bont ES, Fidler V, Meeuwsen T, Scherpen F, Hählen K, Kamps WA. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 2002;8:2856-61.
44. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-5.
45. Janowska-Wieczorek A, Marquez LA, et al. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br J Haematol 1999;105:402-11.
46. Ries C, Loher F, Zang C, Ismair MG, Petrides PE. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res 1999;5:1115-24.
47. Chaudhary AK, Chaudhary S, Ghosh K, Shanmukaiah C, Nadkarni AH. Secretion and expression of matrix metalloproteinase-2 and 9 from bone marrow mononuclear cells in myelodysplastic syndrome and acute myeloid leukemia. Asian Pac J Cancer Prev 2016;17:1519-29.
48. Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, Bruserud O. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. Eur J Haematol 2009;84:239-51.
49. King ME, Rowe JM. Recent developments in acute myelogenous leukemia therapy. Oncologist 2007;12 Suppl 2:14-21.
50. Bauvois B, Nguyen J, Tang R, Billard C, Kolb JP. Types I and II interferons upregulate the costimulatory CD80 molecule in monocytes via interferon regulatory factor-1. Biochem Pharmacol 2009;78:514-22.
51. Bouchet S, Tang R, Fava F, Legrand O, Bauvois B. The CNGRC-GG-D(KLAKLAK)2 peptide induces a caspase-independent, Ca2+-dependent death in human leukemic myeloid cells by targeting surface aminopeptidase N/CD13. Oncotarget 2016;7:19445-67.
52. Bauvois B, Dumont J, Mathiot C, Kolb JP. Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons. Leukemia 2002;16:791-8.
53. Bauvois B, Pramil E, Jondreville L, et al. Relation of neutrophil gelatinase-associated lipocalin overexpression to the resistance to apoptosis of tumor B cells in chronic lymphocytic leukemia. Cancers (Basel) 2020;12:2124.
54. Trocme C, Gaudin P, Berthier S, Barro C, Zaoui P, Morel F. Human B lymphocytes synthesize the 92-kDa gelatinase, matrix metalloproteinase-9. J Biol Chem 1998;273:20677-84.
55. Munaut C, Noel A, Hougrand O, Foidart JM, Boniver J, Deprez M. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer 2003;106:848-55.
56. Bauvois B, Pramil E, Jondreville L, Quiney C, Nguyen-Khac F, Susin SA. Activation of interferon signaling in chronic lymphocytic leukemia cells contributes to apoptosis resistance via a JAK-Src/STAT3/Mcl-1 signaling pathway. Biomedicines 2021;9:188.
58. Paupert J, Mansat-De Mas V, Demur C, Salles B, Muller C. Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle 2008;7:1047-53.
59. Toth M, Gervasi DC, Fridman R. Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells. Cancer Res 1997;57:3159-67.
60. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 1992;267:3581-4.
61. Knäuper V, Smith B, López-Otin C, Murphy G. Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13). Eur J Biochem 1997;248:369-73.
62. Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci 2009;1171:59-76.
63. Tolomeo M, Cascio A. The multifaced role of STAT3 in cancer and its implication for anticancer therapy. Int J Mol Sci 2021;22:603.
64. Vandooren J, Van den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol 2013;48:222-72.
65. Choueiri TK, Kaelin WG, Jr. Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med 2020;26:1519-30.
66. Aref S, Osman E, Mansy S, et al. Prognostic relevance of circulating matrix metalloproteinase-2 in acute myeloid leukaemia patients. Hematol Oncol 2007;25:121-6.
67. Martelli AM, Nyåkern M, Tabellini G, et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006;20:911-28.
68. Dona M, Dell’Aica I, Pezzato E, et al. Hyperforin inhibits cancer invasion and metastasis. Cancer Res 2004;64:6225-32.
69. Kampen KR, Ter Elst A, de Bont ES. Vascular endothelial growth factor signaling in acute myeloid leukemia. Cell Mol Life Sci 2013;70:1307-17.
71. Redondo-Munoz J, Ugarte-Berzal E, Terol MJ, et al. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell 2010;17:160-72.
72. Stefanidakis M, Karjalainen K, Jaalouk DE, et al. Role of leukemia cell invadosome in extramedullary infiltration. Blood 2009;114:3008-17.
73. Kortlepel K, Bendall LJ, Gottlieb DJ. Human acute myeloid leukaemia cells express adhesion proteins and bind to bone marrow fibroblast monolayers and extracellular matrix proteins. Leukemia 1993;7:1174-9.
74. Sell TS, Belkacemi T, Flockerzi V, Beck A. Protonophore properties of hyperforin are essential for its pharmacological activity. Sci Rep 2014;4:7500.
75. Mollinedo F, Gajate C. Lipid rafts as major platforms for signaling regulation in cancer. Adv Biol Regul 2015;57:130-46.
76. George KS, Wu S. Lipid raft: a floating island of death or survival. Toxicol Appl Pharmacol 2012;259:311-9.
78. Salaün C, James DJ, Chamberlain LH. Lipid rafts and the regulation of exocytosis. Traffic 2004;5:255-64.
80. Ouweneel AB, Thomas MJ, Sorci-Thomas MG. The ins and outs of lipid rafts: functions in intracellular cholesterol homeostasis, microparticles, and cell membranes. J Lipid Res 2020;61:676-86.
81. Dell’Agli M, Canavesi M, Galli G, Bellosta S. Dietary polyphenols and regulation of gelatinase expression and activity. Thromb Haemost 2005;93:751-60.
82. Coleman DT, Bigelow R, Cardelli JA. Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation. Mol Cancer Ther 2009;8:214-24.
83. Duhon D, Bigelow RL, Coleman DT, et al. The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells. Mol Carcinog 2010;49:739-49.
84. Mocanu MM, Ganea C, Georgescu L, et al. Epigallocatechin 3-O-gallate induces 67 kDa laminin receptor-mediated cell death accompanied by downregulation of ErbB proteins and altered lipid raft clustering in mammary and epidermoid carcinoma cells. J Nat Prod 2014;77:250-7.
85. Overall CM, Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 2006;94:941-6.
86. Sela-Passwell N, Rosenblum G, Shoham T, Sagi I. Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition? Biochim Biophys Acta 2010;1803:29-38.
87. Raeeszadeh-Sarmazdeh M, Do LD, Hritz BG. Metalloproteinases and their inhibitors: potential for the development of new therapeutics. Cells 2020;9:1313.
88. Bjorklund M, Heikkila P, Koivunen E. Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion. J Biol Chem 2004;279:29589-97.
89. Mantuano E, Inoue G, Li X, et al. The hemopexin domain of matrix metalloproteinase-9 activates cell signaling and promotes migration of schwann cells by binding to low-density lipoprotein receptor-related protein. J Neurosci 2008;28:11571-82.
90. Dufour A, Zucker S, Sampson NS, Kuscu C, Cao J. Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides. J Biol Chem 2010;285:35944-56.
91. Ollauri-Ibáñez C, Astigarraga I. Use of antiangiogenic therapies in pediatric solid tumors. Cancers (Basel) 2021:13.
92. Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet 2016;388:518-29.
93. Schempp CM, Kiss J, Kirkin V, et al. Hyperforin acts as an angiogenesis inhibitor. Planta Med 2005;71:999-1004.
94. Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: a ‘modern’ herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet 2006;45:449-68.
95. Ang CY, Hu L, Heinze TM, et al. Instability of St. John’s wort (Hypericum perforatum L.) and degradation of hyperforin in aqueous solutions and functional beverage. J Agric Food Chem 2004;52:6156-64.
96. Chen Y, Ferguson SS, Negishi M, Goldstein JA. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 2004;308:495-501.
97. Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H. The effect of St John’s wort extracts on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol 2006;62:512-26.
98. Biber A, Fischer H, Romer A, Chatterjee SS. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry 1998;31 Suppl 1:36-43.
99. Schulz HU, Schurer M, Bassler D, Weiser D. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers. Arzneimittelforschung 2005;55:561-8.
100. Franklin M, Chi J, McGavin C, et al. Neuroendocrine evidence for dopaminergic actions of hypericum extract (LI 160) in healthy volunteers. Biol Psychiatry 1999;46:581-4.
101. Gartner M, Muller T, Simon JC, Giannis A, Sleeman JP. Aristoforin, a novel stable derivative of hyperforin, is a potent anticancer agent. Chembiochem 2005;6:171-7.
102. Martinez-Poveda B, Verotta L, Bombardelli E, Quesada AR, Medina MA. Tetrahydrohyperforin and octahydrohyperforin are two new potent inhibitors of angiogenesis. PLoS One 2010;5:e9558.
103. Chauvet S, Barras A, Boukherroub R, Bouron A. Lipid nanocapsules containing the non-ionic surfactant Solutol HS15 inhibit the transport of calcium through hyperforin-activated channels in neuronal cells. Neuropharmacology 2015;99:726-34.
104. Nosratabadi R, Rastin M, Sankian M, Haghmorad D, Mahmoudi M. Hyperforin-loaded gold nanoparticle alleviates experimental autoimmune encephalomyelitis by suppressing Th1 and Th17 cells and upregulating regulatory T cells. Nanomedicine 2016;12:1961-71.
105. Füller J, Kellner T, Gaid M, Beerhues L, Müller-Goymann CC. Stabilization of hyperforin dicyclohexylammonium salt with dissolved albumin and albumin nanoparticles for studying hyperforin effects on 2D cultivation of keratinocytes in vitro. Eur J Pharm Biopharm 2018;126:115-22.
